Replies to post #657 on Dynasil Corporation of America (DYSL)

[jockinmikeg]

I have been adding too. Positive preclinical trial news for XCede and I think this gets some attention, as it almost feels like failure is priced in since it sat on the shelf so long. They have credible partners for the biomedical and we should be hearing results this year. They have done a good job reducing debt, but revenues are lumpy. Optometrics growth should add a few cents per share over the next couple years.

[jockinmikeg]

Long term play for sure, but XCede may bear fruit near-to mid term with positive preclinical data, which may spark some attention after weighing on the books dormant for so long.